🎉 M&A multiples are live!
Check it out!

Jiuzhou Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Jiuzhou Pharmaceutical and similar public comparables like Suven Pharma, Syngene International, and Biocon.

Jiuzhou Pharmaceutical Overview

About Jiuzhou Pharmaceutical

Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based pharmaceutical manufacturer. The company is primarily engaged in the manufacturing, research, development, and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst, and lithium battery materials. Its active pharmaceutical ingredient offerings include Carbamazepine, Duloxetine, Bezafibrate, Meropenem, Sulphadimethoxine Sodium, Oxcarbazepine, and Amprolium, among others. The firm also provides services of new drug contract development and manufacturing organization to the international pharmaceutical giant.


Founded

1973

HQ

China
Employees

4.9K+

Financials

LTM Revenue $736M

LTM EBITDA $172M

EV

$1.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Jiuzhou Pharmaceutical Financials

Jiuzhou Pharmaceutical has a last 12-month revenue of $736M and a last 12-month EBITDA of $172M.

In the most recent fiscal year, Jiuzhou Pharmaceutical achieved revenue of $711M and an EBITDA of $160M.

Jiuzhou Pharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Jiuzhou Pharmaceutical valuation multiples based on analyst estimates

Jiuzhou Pharmaceutical P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $761M $711M XXX XXX XXX
Gross Profit $260M $287M XXX XXX XXX
Gross Margin 34% 40% XXX XXX XXX
EBITDA $218M $160M XXX XXX XXX
EBITDA Margin 29% 22% XXX XXX XXX
Net Profit $127M $142M XXX XXX XXX
Net Margin 17% 20% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Jiuzhou Pharmaceutical Stock Performance

As of April 15, 2025, Jiuzhou Pharmaceutical's stock price is CNY 13 (or $2).

Jiuzhou Pharmaceutical has current market cap of CNY 11.4B (or $1.6B), and EV of CNY 9.1B (or $1.3B).

See Jiuzhou Pharmaceutical trading valuation data

Jiuzhou Pharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.3B $1.6B XXX XXX XXX XXX $0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Jiuzhou Pharmaceutical Valuation Multiples

As of April 15, 2025, Jiuzhou Pharmaceutical has market cap of $1.6B and EV of $1.3B.

Jiuzhou Pharmaceutical's trades at 1.7x LTM EV/Revenue multiple, and 7.3x LTM EBITDA.

Analysts estimate Jiuzhou Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Jiuzhou Pharmaceutical and 10K+ public comps

Jiuzhou Pharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.3B XXX XXX XXX
EV/Revenue 1.8x XXX XXX XXX
EV/EBITDA 7.8x XXX XXX XXX
P/E 18.8x XXX XXX XXX
P/E/Growth 0.6x XXX XXX XXX
EV/FCF 88.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Jiuzhou Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Jiuzhou Pharmaceutical Valuation Multiples

Jiuzhou Pharmaceutical's NTM/LTM revenue growth is 11%

Jiuzhou Pharmaceutical's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $24K for the same period.

Over next 12 months, Jiuzhou Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Jiuzhou Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Jiuzhou Pharmaceutical and other 10K+ public comps

Jiuzhou Pharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -7% XXX XXX XXX XXX
EBITDA Margin 22% XXX XXX XXX XXX
EBITDA Growth -27% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 33% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $24K XXX XXX XXX XXX
S&M Expenses to Revenue 1% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue 6% XXX XXX XXX XXX
Opex to Revenue 16% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Jiuzhou Pharmaceutical Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Suven Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Jiuzhou Pharmaceutical M&A and Investment Activity

Jiuzhou Pharmaceutical acquired  XXX companies to date.

Last acquisition by Jiuzhou Pharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Jiuzhou Pharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Jiuzhou Pharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Jiuzhou Pharmaceutical

When was Jiuzhou Pharmaceutical founded? Jiuzhou Pharmaceutical was founded in 1973.
Where is Jiuzhou Pharmaceutical headquartered? Jiuzhou Pharmaceutical is headquartered in China.
How many employees does Jiuzhou Pharmaceutical have? As of today, Jiuzhou Pharmaceutical has 4.9K+ employees.
Is Jiuzhou Pharmaceutical publicy listed? Yes, Jiuzhou Pharmaceutical is a public company listed on SHG.
What is the stock symbol of Jiuzhou Pharmaceutical? Jiuzhou Pharmaceutical trades under 603456 ticker.
When did Jiuzhou Pharmaceutical go public? Jiuzhou Pharmaceutical went public in 2014.
Who are competitors of Jiuzhou Pharmaceutical? Similar companies to Jiuzhou Pharmaceutical include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics.
What is the current market cap of Jiuzhou Pharmaceutical? Jiuzhou Pharmaceutical's current market cap is $1.6B
What is the current revenue of Jiuzhou Pharmaceutical? Jiuzhou Pharmaceutical's last 12-month revenue is $736M.
What is the current EBITDA of Jiuzhou Pharmaceutical? Jiuzhou Pharmaceutical's last 12-month EBITDA is $172M.
What is the current EV/Revenue multiple of Jiuzhou Pharmaceutical? Current revenue multiple of Jiuzhou Pharmaceutical is 1.7x.
What is the current EV/EBITDA multiple of Jiuzhou Pharmaceutical? Current EBITDA multiple of Jiuzhou Pharmaceutical is 7.3x.
What is the current revenue growth of Jiuzhou Pharmaceutical? Jiuzhou Pharmaceutical revenue growth between 2023 and 2024 was -7%.
Is Jiuzhou Pharmaceutical profitable? Yes, Jiuzhou Pharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.